Insilico Medicine receives IND approval for novel AI-designed USP1 inhibitor for cancer
Insilico Medicine (“Insilico”), a generative artificial intelligence (AI)-driven clinical stage drug discovery company, today announced that the U.S. Food and Drug Administration (FDA) recently approved...